Search

Your search keyword '"Storey, Robert F"' showing total 1,752 results
Start Over Author "Storey, Robert F"
1,752 results on '"Storey, Robert F"'

1. Intraoperative haemoadsorption for antithrombotic drug removal during cardiac surgery: initial report of the international safe and timely antithrombotic removal (STAR) registry

Author

Schmoeckel, Michael, Thielmann, Matthias, Hassan, Kambiz, Geidel, Stephan, Schmitto, Jan, Meyer, Anna L., Vitanova, Keti, Liebold, Andreas, Marczin, Nandor, Bernardi, Martin H., Tandler, Rene, Lindstedt, Sandra, Matejic-Spasic, Marijana, Wendt, Daniel, Deliargyris, Efthymios N., and Storey, Robert F.

Published
2024
Full Text
View/download PDF

2. De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis

Author

Gorog, Diana A., Ferreiro, Jose Luis, Ahrens, Ingo, Ako, Junya, Geisler, Tobias, Halvorsen, Sigrun, Huber, Kurt, Jeong, Young-Hoon, Navarese, Eliano P., Rubboli, Andrea, Sibbing, Dirk, Siller-Matula, Jolanta M., Storey, Robert F., Tan, Jack W. C., ten Berg, Jurrien M., Valgimigli, Marco, Vandenbriele, Christophe, and Lip, Gregory Y. H.

Published
2023
Full Text
View/download PDF

3. Design and rationale of the CLEAR SYNERGY (OASIS 9) trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone vs placebo in patients with myocardial infarction

Author

d'Entremont, Marc-André, Lee, Shun Fu, Mian, Rajibul, Kedev, Sasko, Montalescot, Gilles, Cornel, Jan Hein, Stankovic, Goran, Moreno, Raul, Storey, Robert F., Henry, Timothy D., Skuriat, Elizabeth, Tyrwhitt, Jessica, Mehta, Shamir R., Devereaux, P.J., Eikelboom, John, Cairns, John A., Pitt, Bertram, and Jolly, Sanjit S.

Published
2024
Full Text
View/download PDF

4. SYNERGY—Everolimus-Eluting Stent With a Bioabsorbable Polymer in ST-Elevation Myocardial Infarction: CLEAR SYNERGY OASIS-9 Registry

Author

Jolly, Sanjit S., Lee, Shun Fu, Mian, Rajibul, Kedev, Sasko, Lavi, Shahar, Moreno, Raul, Montalescot, Gilles, Hillani, Ali, Henry, Timothy D., Asani, Valon, Storey, Robert F., Silvain, Johanne, Spratt, James C.S., d'Entremont, Marc-André, Stankovic, Goran, Zafirovska, Biljana, Natarajan, Madhu K., Sabate, Manel, Shreenivas, Satya, Pinilla-Echeverri, Natalia, Sheth, Tej, Altisent, Omar Abdul-Jawad, Ribas, Núria, Skuriat, Elizabeth, Tyrwhitt, Jessica, and Mehta, Shamir R.

Published
2024
Full Text
View/download PDF

7. Effects of complete revascularization according to age in patients with ST-segment elevation myocardial infarction and multivessel disease (COMPLETE-AGE)

Author

Bainey, Kevin R., Wood, David A., Bossard, Matthias, Campo, Gianluca, Cantor, Warren J., Lavi, Shahar, Madan, Mina, Mehran, Roxana, Pinilla-Echeverri, Natalia, Rao, Sunil, Sarma, Jaydeep, Sheth, Tej, Stankovic, Goran, Steg, Phillipe Gabriel, Storey, Robert F., Tanguay, Jean-Francois, Velianou, James L., Welsh, Robert C., Mani, Thenmozhi, Cairns, John A., and Mehta, Shamir R.

Published
2024
Full Text
View/download PDF

12. P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention

Author

Capodanno, Davide, Baber, Usman, Bhatt, Deepak L., Collet, Jean-Philippe, Dangas, George, Franchi, Francesco, Gibson, C. Michael, Gwon, Hyeon-Cheol, Kastrati, Adnan, Kimura, Takeshi, Lemos, Pedro A., Lopes, Renato D., Mehran, Roxana, O’Donoghue, Michelle L., Rao, Sunil V., Rollini, Fabiana, Serruys, Patrick W., Steg, Philippe G., Storey, Robert F., Valgimigli, Marco, Vranckx, Pascal, Watanabe, Hirotoshi, Windecker, Stephan, and Angiolillo, Dominick J.

Published
2022
Full Text
View/download PDF

14. Complete Revascularization Versus Culprit-Lesion-Only PCI in STEMI Patients With Diabetes and Multivessel Coronary Artery Disease: Results From the COMPLETE Trial

Author

Oqab, Zardasht, Kunadian, Vijay, Wood, David A., Storey, Robert F., Rao, Sunil V., Mehran, Roxana, Pinilla-Echeverri, Natalia, Mani, Thenmozhi, Boone, Robert H., Kassam, Saleem, Bossard, Matthias, Mansour, Samer, Ball, Warren, Sibbald, Matthew, Valettas, Nicholas, Moreno, Raul, Steg, Philippe Gabriel, Cairns, John A., and Mehta, Shamir R.

Published
2023
Full Text
View/download PDF

15. Clinical decision aids and computed tomography coronary angiography in patients with suspected acute coronary syndrome

Author

Wang, Kang-Ling, primary, Taggart, Caelan, additional, McDermott, Michael, additional, O'Brien, Rachel, additional, Oatey, Katherine, additional, Keating, Liza, additional, Storey, Robert F, additional, Felmeden, Dirk, additional, Curzen, Nick, additional, Kardos, Attila, additional, Roobottom, Carl, additional, Smith, Jason, additional, Goodacre, Steve, additional, Newby, David E, additional, and Gray, Alasdair J, additional

Published
2024
Full Text
View/download PDF

16. Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium

Author

Gorog, Diana A., Storey, Robert F., Gurbel, Paul A., Tantry, Udaya S., Berger, Jeffrey S., Chan, Mark Y., Duerschmied, Daniel, Smyth, Susan S., Parker, William A. E., Ajjan, Ramzi A., Vilahur, Gemma, Badimon, Lina, Berg, Jurrien M. ten, Cate, Hugo ten, Peyvandi, Flora, Wang, Taia T., and Becker, Richard C.

Published
2022
Full Text
View/download PDF

19. Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium

Author

Capodanno, Davide, Mehran, Roxana, Krucoff, Mitchell W., Baber, Usman, Bhatt, Deepak L., Capranzano, Piera, Collet, Jean-Philippe, Cuisset, Thomas, De Luca, Giuseppe, De Luca, Leonardo, Farb, Andrew, Franchi, Francesco, Gibson, C. Michael, Hahn, Joo-Yong, Hong, Myeong-Ki, James, Stefan, Kastrati, Adnan, Kimura, Takeshi, Lemos, Pedro A., Lopes, Renato D., Magee, Adrian, Matsumura, Ryosuke, Mochizuki, Shuichi, O’Donoghue, Michelle L., Pereira, Naveen L., Rao, Sunil V., Rollini, Fabiana, Shirai, Yuko, Sibbing, Dirk, Smits, Peter C., Steg, P. Gabriel, Storey, Robert F., ten Berg, Jurrien, Valgimigli, Marco, Vranckx, Pascal, Watanabe, Hirotoshi, Windecker, Stephan, Serruys, Patrick W., Yeh, Robert W., Morice, Marie-Claude, and Angiolillo, Dominick J.

Published
2023
Full Text
View/download PDF

20. Antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention.

Author

Sammut, Mark Anthony and Storey, Robert F

Subjects
PLATELET aggregation inhibitors, FIBRINOLYTIC agents, PERCUTANEOUS coronary intervention, ATRIAL fibrillation, PRASUGREL
Abstract

Introduction: Patients who undergo percutaneous coronary intervention (PCI) with stenting usually require a period of dual antiplatelet therapy (DAPT) but, when an indication for long-term oral anticoagulation (OAC) such as atrial fibrillation (AF) coexists, triple antithrombotic therapy (TAT) with DAPT and OAC causes concern for excessive bleeding. Achieving the right balance between bleeding and adequate protection from ischemic events remains an issue of debate and subject to ongoing investigation of various antithrombotic regimens and durations. Areas covered: This review describes the landmark clinical trials comparing TAT to a period of dual antithrombotic therapy (DAT) and subsequent meta-analyses. It also describes the international recommendations that have been derived from this evidence and identifies outstanding issues that could be addressed in upcoming or future trials. Expert opinion: The current recommended default strategy of a short period of TAT with clopidogrel followed by the withdrawal of aspirin faces a challenge from the prospect of more consistent P2Y12 inhibition provided by ticagrelor and prasugrel. Ticagrelor monotherapy has already been trialed in patients after PCI without an indication for OAC. DAT with ticagrelor or prasugrel immediately post-procedure could emerge as a comparably safe and more efficacious regimen than one involving clopidogrel in the right setting. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics

Author

Morales-Rosado, Joel A., Goel, Kashish, Zhang, Lingxin, Åkerblom, Axel, Baheti, Saurabh, Black, John L., Eriksson, Niclas, Wallentin, Lars, James, Stefan, Storey, Robert F., Goodman, Shaun G., Jenkins, Gregory D., Eckloff, Bruce W., Bielinski, Suzette J., Sicotte, Hugues, Johnson, Stephen, Roger, Veronique L., Wang, Liewei, Weinshilboum, Richard, Klee, Eric W., Rihal, Charanjit S., and Pereira, Naveen L.

Published
2021
Full Text
View/download PDF

24. Temporal biomarker concentration patterns during the early course of acute coronary syndrome

Author

Eggers, Kai M., Batra, Gorav, Lindahl, Bertil, Lakic, Tatevik, Lindbäck, Johan, Budaj, Andrzej, Cornel, Jan H., Giannitsis, Evangelos, Katus, Hugo A., Storey, Robert F., Becker, Richard C., Siegbahn, Agneta, Wallentin, Lars, Eggers, Kai M., Batra, Gorav, Lindahl, Bertil, Lakic, Tatevik, Lindbäck, Johan, Budaj, Andrzej, Cornel, Jan H., Giannitsis, Evangelos, Katus, Hugo A., Storey, Robert F., Becker, Richard C., Siegbahn, Agneta, and Wallentin, Lars

Abstract

Objectives: Biomarker concentrations and their changes during acute coronary syndrome (ACS) provide clinically useful information on pathophysiological processes, e.g. myocardial necrosis, hemodynamic stress and inflammation. However, current evidence on temporal biomarker patterns early during ACS is limited, and studies investigating multiple biomarkers are lacking. Methods: We measured concentrations of high-sensitivity cardiac troponin T (hs-cTnT) and I (hs-cTnI), NT-terminal pro-B-type natriuretic peptide, C-reactive protein, and growth-differentiation factor-15 (GDF-15) in plasma samples obtained at randomization in ACS patients from the PLATelet inhibition and patient Outcomes (PLATO) trial. Linear regressions with interaction analyses were used to investigate the associations of biomarker concentrations with the time from symptom onset and to model temporal biomarker concentration patterns. Results: The study population consisted of 16,944 patients (median age 62 years; 71.3 % males) with 6,853 (40.3 %) having ST-elevation myocardial infarction (STEMI) and 10,141 (59.7 %) having non-ST-elevation ACS (NSTE-ACS). Concentrations of all biomarkers were associated with time from symptom onset (pinteraction<0.001), apart for GDF-15 (pinteraction=0.092). Concentration increases were more pronounced in STEMI compared to NSTE-ACS. Temporal biomarker patterns for hs-cTnT and hs-cTnI were different depending on sex whereas biomarker patterns for the other biomarkers were similar in cohorts defined by age and sex. Conclusions: Temporal concentration patterns differ for various biomarkers early during ACS, reflecting the variability in the activation and duration of different pathophysiological processes, and the amount of injured myocardium. Our data emphasize that the time elapsed from symptom onset should be considered for the interpretation of biomarker results in ACS.

Published
2024
Full Text
View/download PDF

25. Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome

Author

Valgimigli, Marco, Landi, Antonio, Angiolillo, Dominick J., Baber, Usman, Bhatt, Deepak L., Bonaca, Marc P., Capodanno, Davide, Cohen, David J., Gibson, C. Michael, James, Stefan, Kimura, Takeshi, Lopes, Renato D., Mehta, Shamir R., Montalescot, Gilles, Sibbing, Dirk, Steg, P. Gabriel, Stone, Gregg W., Storey, Robert F., Vranckx, Pascal, Windecker, Stephan, Mehran, Roxana, Valgimigli, Marco, Landi, Antonio, Angiolillo, Dominick J., Baber, Usman, Bhatt, Deepak L., Bonaca, Marc P., Capodanno, Davide, Cohen, David J., Gibson, C. Michael, James, Stefan, Kimura, Takeshi, Lopes, Renato D., Mehta, Shamir R., Montalescot, Gilles, Sibbing, Dirk, Steg, P. Gabriel, Stone, Gregg W., Storey, Robert F., Vranckx, Pascal, Windecker, Stephan, and Mehran, Roxana

Abstract

For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) has been the only class I recommendation on DAPT in American and European guidelines, which has resulted in 12-month durations of DAPT therapy being the most frequently implemented in ACS patients undergoing percutaneous coronary intervention (PCI) across the globe. Twelve-month DAPT was initially grounded in the results of the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) trial, which, by design, studied DAPT versus no DAPT rather than the optimal DAPT duration. The average DAPT duration in this study was 9 months, not 12 months. Subsequent ACS studies, which were not designed to assess DAPT duration, rather its composition (aspirin with prasugrel or ticagrelor compared with clopidogrel) were further interpreted as supportive evidence for 12-month DAPT duration. In these studies, the median DAPT duration was 9 or 15 months for ticagrelor and prasugrel, respectively. Several subsequent studies questioned the 12-month regimen and suggested that DAPT duration should either be fewer than 12 months in patients at high bleeding risk or more than 12 months in patients at high ischemic risk who can safely tolerate the treatment. Bleeding, rather than ischemic risk assessment, has emerged as a treatment modifier for maximizing the net clinical benefit of DAPT, due to excessive bleeding and no clear benefit of prolonged treatment regimens in high bleeding risk patients. Multiple DAPT de-escalation treatment strategies, including switching from prasugrel or ticagrelor to clopidogrel, reducing the dose of prasugrel or ticagrelor, and shortening DAPT duration while maintaining monotherapy with ticagrelor, have been consistently shown to reduce bleeding without increasing fatal or nonfatal cardiovascular or cerebral ischemic risks compared with 12-month DAPT. However, 12-month DAPT remains the only class-I DAPT recommendation for patients with ACS despite the la

Published
2024
Full Text
View/download PDF

27. Antithrombotic therapy in patients with acute coronary syndrome : similarities and differences between a European expert consensus document and the 2023 European Society of Cardiology guidelines

Author

Landi, Antonio, Aboyans, Victor, Angiolillo, Dominick J., Atar, Dan, Capodanno, Davide, Fox, Keith A. A., Halvorsen, Sigrun, James, Stefan, Juni, Peter, Leonardi, Sergio, Mehran, Roxana, Montalescot, Gilles, Navarese, Eliano Pio, Niebauer, Josef, Oliva, Angelo, Piccolo, Raffaele, Price, Susanna, Storey, Robert F., Voeller, Heinz, Vranckx, Pascal, Windecker, Stephan, Valgimigli, Marco, Landi, Antonio, Aboyans, Victor, Angiolillo, Dominick J., Atar, Dan, Capodanno, Davide, Fox, Keith A. A., Halvorsen, Sigrun, James, Stefan, Juni, Peter, Leonardi, Sergio, Mehran, Roxana, Montalescot, Gilles, Navarese, Eliano Pio, Niebauer, Josef, Oliva, Angelo, Piccolo, Raffaele, Price, Susanna, Storey, Robert F., Voeller, Heinz, Vranckx, Pascal, Windecker, Stephan, and Valgimigli, Marco

Abstract

Antithrombotic therapy represents the cornerstone of the pharmacological treatment in patients with acute coronary syndrome (ACS). The optimal combination and duration of antithrombotic therapy is still matter of debate requiring a critical assessment of patient comorbidities, clinical presentation, revascularization modality, and/or optimization of medical treatment. The 2023 European Society of Cardiology (ESC) guidelines for the management of patients with ACS encompassing both patients with and without ST segment elevation ACS have been recently published. Shortly before, a European expert consensus task force produced guidance for clinicians on the management of antithrombotic therapy in patients with ACS as well as chronic coronary syndrome. The scope of this manuscript is to provide a critical appraisal of differences and similarities between the European consensus paper and the latest ESC recommendations on oral antithrombotic regimens in ACS patients.

Published
2024
Full Text
View/download PDF

28. Modelled impact of virtual fractional flow reserve in patients undergoing coronary angiography (VIRTU-4).

Author

Ghobrial, Mina, Haley, Hazel, Gosling, Rebecca, Taylor, Daniel James, Richardson, James, Morgan, Kenneth, Barmby, David, Iqbal, Javaid, Krishnamurthy, Arvindra, Singh, Rajender, Conway, Dwayne, Hall, Ian, Adam, Zulfiquar, Wheeldon, Nigel, Grech, Ever D., Storey, Robert F., Rothman, Alexander, Payne, Gillian, Tahir, Muhammad Naeem, and Smith, Simon

Subjects
CORONARY artery bypass, CORONARY circulation, CHRONIC total occlusion, CARDIAC magnetic resonance imaging, SAMPLE size (Statistics), MYOCARDIAL infarction, CHEST pain, DRUG-eluting stents, ORAL medication
Published
2024
Full Text
View/download PDF

30. Duration of triple antithrombotic therapy and clinical outcomes after percutaneous coronary intervention in atrial fibrillation.

Author

Sammut, Mark A., Conway, Dwayne, Iqbal, Javaid, Krishnamurthy, Arvindra, Morgan, Kenneth P., Morris, Paul D., Richardson, James D., Rothman, Alexander M. K., Gunn, Julian P., and Storey, Robert F.

Subjects
PERCUTANEOUS coronary intervention, FIBRINOLYTIC agents, ATRIAL fibrillation, MYOCARDIAL infarction, P-waves (Electrocardiography), TREATMENT effectiveness
Abstract

Triple antithrombotic therapy (TAT) with aspirin, a P2Y12 inhibitor, and oral anticoagulation in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) raises concerns about increased bleeding. Regimens incorporating more potent P2Y12 inhibitors over clopidogrel have not been investigated adequately. A retrospective observational study was performed on 387 patients with AF receiving TAT for 1 month (n = 236) or ≤1 week (n = 151) after PCI. Major and clinically relevant non-major bleeding and major adverse cardiac and cerebrovascular events (MACCE) were assessed up to 30 days post-procedure. Bleeding was less frequent with ≤1 week versus 1 month of TAT (3.3 vs 9.3%; p = 0.025) while MACCE were similar (4.6 vs 4.7%; p = 0.998). No differences in bleeding or MACCE were observed between ticagrelor/prasugrel and clopidogrel regimens. For patients receiving ≤1 week of TAT, no excess of MACCE was seen in the subgroup given no further aspirin post-PCI compared with those given aspirin for up to 1 week (3.6 vs 5.2%). TAT post-PCI for ≤1 week was associated with less bleeding despite greater use of ticagrelor/prasugrel but similar MACCE versus 1-month TAT. These findings support further studies on safety and efficacy of dual therapy with ticagrelor/prasugrel immediately after PCI. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of Cardiology guidelines

Author

Landi, Antonio, primary, Aboyans, Victor, additional, Angiolillo, Dominick J, additional, Atar, Dan, additional, Capodanno, Davide, additional, Fox, Keith A A, additional, Halvorsen, Sigrun, additional, James, Stefan, additional, Jüni, Peter, additional, Leonardi, Sergio, additional, Mehran, Roxana, additional, Montalescot, Gilles, additional, Navarese, Eliano Pio, additional, Niebauer, Josef, additional, Oliva, Angelo, additional, Piccolo, Raffaele, additional, Price, Susanna, additional, Storey, Robert F, additional, Völler, Heinz, additional, Vranckx, Pascal, additional, Windecker, Stephan, additional, and Valgimigli, Marco, additional

Published
2024
Full Text
View/download PDF

36. Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction: COMPLETE Trial

Author

Wood, David A., Cairns, John A., Wang, Jia, Mehran, Roxana, Storey, Robert F., Nguyen, Helen, Meeks, Brandi, Kunadian, Vijay, Tanguay, Jean-Francois, Kim, Hahn-Ho, Cheema, Asim, Dehghani, Payam, Natarajan, Madhu K., Jolly, Sanjit S., Amerena, John, Keltai, Matyas, James, Stefan, Hlinomaz, Ota, Niemela, Kari, AlHabib, Khalid, Lewis, Basil S., Nguyen, Michel, Sarma, Jaydeep, Dzavik, Vladimir, Della Siega, Anthony, and Mehta, Shamir R.

Published
2019
Full Text
View/download PDF

37. The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial

Author

Ono, Masafumi, Chichareon, Ply, Tomaniak, Mariusz, Kawashima, Hideyuki, Takahashi, Kuniaki, Kogame, Norihiro, Modolo, Rodrigo, Hara, Hironori, Gao, Chao, Wang, Rutao, Walsh, Simon, Suryapranata, Harry, da Silva, Pedro Canas, Cotton, James, Koning, René, Akin, Ibrahim, Rensing, Benno J. W. M., Garg, Scot, Wykrzykowska, Joanna J., Piek, Jan J., Jüni, Peter, Hamm, Christian, Steg, Philippe Gabriel, Valgimigli, Marco, Windecker, Stephan, Storey, Robert F., Onuma, Yoshinobu, Vranckx, Pascal, and Serruys, Patrick W.

Published
2020
Full Text
View/download PDF

38. Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial

Author

Tomaniak, Mariusz, Chichareon, Ply, Klimczak-Tomaniak, Dominika, Takahashi, Kuniaki, Kogame, Norihiro, Modolo, Rodrigo, Wang, Rutao, Ono, Masafumi, Hara, Hironori, Gao, Chao, Kawashima, Hideyuki, Rademaker-Havinga, Tessa, Garg, Scot, Curzen, Nick, Haude, Michael, Kochman, Janusz, Gori, Tommaso, Montalescot, Gilles, Angiolillo, Dominick J., Capodanno, Davide, Storey, Robert F., Hamm, Christian, Vranckx, Pascal, Valgimigli, Marco, Windecker, Stephan, Onuma, Yoshinobu, Serruys, Patrick W., and Anderson, Richard

Published
2020
Full Text
View/download PDF

39. Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease

Author

Capodanno, Davide, Bhatt, Deepak L., Eikelboom, John W., Fox, Keith A. A., Geisler, Tobias, Michael Gibson, C., Gonzalez-Juanatey, Jose Ramon, James, Stefan, Lopes, Renato D., Mehran, Roxana, Montalescot, Gilles, Patel, Manesh, Steg, P. Gabriel, Storey, Robert F., Vranckx, Pascal, Weitz, Jeffrey I., Welsh, Robert, Zeymer, Uwe, and Angiolillo, Dominick J.

Published
2020
Full Text
View/download PDF

40. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention

Author

Sibbing, Dirk, Aradi, Daniel, Alexopoulos, Dimitrios, ten Berg, Jurrien, Bhatt, Deepak L., Bonello, Laurent, Collet, Jean-Philippe, Cuisset, Thomas, Franchi, Francesco, Gross, Lisa, Gurbel, Paul, Jeong, Young-Hoon, Mehran, Roxana, Moliterno, David J., Neumann, Franz-Josef, Pereira, Naveen L., Price, Matthew J., Sabatine, Marc S., So, Derek Y.F., Stone, Gregg W., Storey, Robert F., Tantry, Udaya, Trenk, Dietmar, Valgimigli, Marco, Waksman, Ron, and Angiolillo, Dominick J.

Published
2019
Full Text
View/download PDF

42. Contributors

Author

Angiolillo, Dominick J., primary, Brener, Michael I., additional, Brener, Sorin J., additional, Capodanno, Davide, additional, Claessen, Bimmer, additional, Costa, Francesco, additional, Gibson, C. Michael, additional, Goel, Ridhima, additional, Greco, Antonio, additional, Lee, Chang Hoon, additional, Mehran, Roxana, additional, Mihatov, Nino, additional, Nicolas, Johny, additional, Phillips, Adam T., additional, Ranard, Lauren S., additional, Sattur, Sudhakar, additional, Storey, Robert F., additional, Valgimigli, Marco, additional, Verheugt, Freek W.A., additional, and Yeh, Robert, additional

Published
2021
Full Text
View/download PDF

45. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure

Author

James, Stefan, primary, Erlinge, David, additional, Storey, Robert F., additional, McGuire, Darren K., additional, de Belder, Mark, additional, Eriksson, Niclas, additional, Andersen, Kasper, additional, Austin, David, additional, Arefalk, Gabriel, additional, Carrick, David, additional, Hofmann, Robin, additional, Hoole, Stephen P., additional, Jones, Daniel A., additional, Lee, Kelvin, additional, Tygesen, Hans, additional, Johansson, Peter A., additional, Langkilde, Anna Maria, additional, Ridderstråle, Wilhelm, additional, Parvaresh Rizi, Ehsan, additional, Deanfield, John, additional, and Oldgren, Jonas, additional

Published
2023
Full Text
View/download PDF

48. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients with Atrial Fibrillation After Acute Coronary Syndrome or PCI: Insights from The AUGUSTUS Trial

Author

Hijazi, Ziad, Alexander, John H., Li, Zhuokai, Wojdyla, Daniel M., Mehran, Roxana, Granger, Christopher B., Parkhomenko, Alexander, Bahit, M. Cecilia, Windecker, Stephan, Aronson, Ronald, Berwanger, Otavio, Halvorsen, Sigrun, de Waha-Thiele, Suzanne, Sinnaeve, Peter, Darius, Harald, Storey, Robert F., and Lopes, Renato D.

Published
2021
Full Text
View/download PDF

50. Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment–Elevation Myocardial Infarction: Insights From the COMPLETE Trial

Author

Dehghani, Payam, Cantor, Warren J., Wang, Jia, Wood, David A., Storey, Robert F., Mehran, Roxana, Bainey, Kevin R., Welsh, Robert C., Rodés-Cabau, Josep, Rao, Sunil, Lavi, Shahar, Velianou, James L., Natarajan, Madhu K., Ziakas, Antonios, Guiducci, Vincenzo, Fernández-Avilés, Francisco, Cairns, John A., and Mehta, Shamir R.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results